Response to letter Re: Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies.

van Not, Olivier J; Blokx, Willeke A M; Wouters, Michel W J M; Suijkerbuijk, Karijn P M

van Not, Olivier J; Blokx, Willeke A M; Wouters, Michel W J M; Suijkerbuijk, Karijn P M.

Afiliação

van Not OJ; Scientific Bureau, Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, Leiden 2333AA, the Netherlands; Department of Medical Oncology, University Medical Centre Utrecht, Heidelberglaan 100, Utrecht 3584CX, the Netherlands. Electronic address: O.J.vanNot@umcutrecht.nl.
Blokx WAM; Department of Pathology, University Medical Centre Utrecht, Heidelberglaan 100, Utrecht 3584CX, the Netherlands.
Wouters MWJM; Scientific Bureau, Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, Leiden 2333AA, the Netherlands; Department of Biomedical Data Sciences, Leiden University Medical Centre, Einthovenweg 20, Leiden 2333ZC, the Netherlands; Department of Surgical Oncology, Netherlands Cancer Institute, Plesm
Suijkerbuijk KPM; Department of Medical Oncology, University Medical Centre Utrecht, Heidelberglaan 100, Utrecht 3584CX, the Netherlands.

Eur J Cancer ; 191: 112983, 2023 09.

Article em En | MEDLINE | ID: mdl-37537090

Assuntos

Neoplasias Hematológicas; Melanoma; Humanos; Melanoma/patologia; Neoplasias Hematológicas/tratamento farmacológico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Hematológicas / Melanoma Limite: Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google